Telbivudine contraindications: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Telbivudine}} {{CMG}} ==Contraindications== Combination of Tyzeka with pegylated interferon alfa-2a is contraindicated because of increased risk of peripheral neu...")
 
mNo edit summary
 
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Telbivudine}}
{{Telbivudine}}
{{CMG}}
{{CMG}}; {{AE}} {{SS}}


==Contraindications==
==Contraindications==
Combination of Tyzeka with pegylated interferon alfa-2a is contraindicated because of increased risk of peripheral neuropathy [see Warnings and Precautions (5.4) and Drug Interactions (7)].<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022011s013lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022011s013lbl.pdf | publisher = |date = | accessdate = }}</ref>


Combination of Tyzeka with [[pegylated interferon alfa-2a]] is contraindicated because of increased risk of [[peripheral neuropathy]] [see Warnings and Precautions (5.4) and Drug Interactions (7)].<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022011s013lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022011s013lbl.pdf | publisher = |date = | accessdate = }}</ref>


==References==
==References==
Line 12: Line 12:
{{FDA}}
{{FDA}}


[[Category:Antiviral]]
[[Category:Antibiotics]]
[[Category:Wikinfect]]
[[Category:Wikinfect]]

Latest revision as of 20:42, 2 January 2014

Telbivudine
TYZEKA® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Contraindications

Combination of Tyzeka with pegylated interferon alfa-2a is contraindicated because of increased risk of peripheral neuropathy [see Warnings and Precautions (5.4) and Drug Interactions (7)].[1]

References

  1. "http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022011s013lbl.pdf" (PDF). External link in |title= (help)

Adapted from the FDA Package Insert.